SouthState Corp’s Ultragenyx Pharmaceutical RARE Stock Holding History

SouthState Corp’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5	Closed	-$115	–	1371
2025 Q4	$115	Hold	5	–	–	﹤0.01%	1309
2025 Q3	$151	Buy	+5	New	+$150	﹤0.01%	1310
2025 Q2	–	Sell	-25	Closed	-$906	–	1768
2025 Q1	$906	Buy	+25	New	+$1.04K	﹤0.01%	1366

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

SouthState Corp's RARE Position: Q1 2026 in Review

SouthState Corp sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 5 shares — an estimated $115 sold.

SouthState Corp first reported a position in RARE in Q1 2025 and held it in 3 quarters. The position peaked at $906 in Q1 2025. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

SouthState Corp reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
SouthState Corp sold 5 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $115.
SouthState Corp first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and held it in 3 quarters.
SouthState Corp's Ultragenyx Pharmaceutical position peaked at $906 in Q1 2025.
298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on SouthState Corp's 13F filing for Q1 2026, filed 5 May 2026.